

CFT7455

Chemical Properties

CAS No. : 2504235-67-8


Formula: C₂₈H₂₇N₃O₄

Molecular Weight: 469.53

Keep away from direct sunlight

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	CFT7455 (Cemsidomide) is an anti-cancer agent showing high affinity to the cereblon E3 ligase with a K _d of 0.9 nM. CFT7455 is an orally active degrader of zinc finger transcription factors Ikaros (IKZF1), and Aiolos (IKZF3).
Targets(IC50)	Ligands for E3 Ligase, Molecular Glues, IKZF
In vitro	CFT7455 enables potent cell growth inhibition in both previously untreated NCIH929 multiple myeloma cell lines with an IC ₅₀ of 0.071 nM and NCIH929 cells made resistant to both lenalidomide and pomalidomide with an IC ₅₀ of 2.3 nM. CFT7455 promotes the degradation of >75% of steady state IKZF1 in multiple myeloma cells within 1.5 hours at 0.3 nM[1].
In vivo	In mouse xenograft tumor models, CFT7455 (3 µg/kg-100 µg/kg) led to durable tumor regression and demonstrates dose-dependent efficacy[1].

Solubility Information

Solubility	DMSO: 20 mg/mL (42.6 mM), Sonication and heating to 60°C are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.26 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1298 mL	10.6489 mL	21.2979 mL
5 mM	0.426 mL	2.1298 mL	4.2596 mL
10 mM	0.213 mL	1.0649 mL	2.1298 mL
50 mM	0.0426 mL	0.213 mL	0.426 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

David Proia, et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1.
Fuchs O. Targeting cereblon in hematologic malignancies. Blood Rev. 2023 Jan;57:100994.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481